Does Rallies show Form 4 insider transactions for BBIO?

Yes. Rallies tracks BBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.

BBIO (BridgeBio Pharma, Inc. Common Stock) Stock Analysis - Insider Trades

BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, BBIO trades at $67.69 with a market cap of $12.79B and a P/E ratio of -18.26. BBIO moved +3.41% today. Year to date, BBIO is -7.08%; over the trailing twelve months it is +102.37%. Its 52-week range spans $21.72 to $84.94. Analyst consensus is strong buy with an average price target of $109.00. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BBIO stock inside the company?

Recent BBIO insider activity includes Scott Randal W. sold 6.20K, Scott Randal W. sold 2.09K, Scott Randal W. sold 1.51K, Scott Randal W. sold 200, and Kumar Neil sold 13.97K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BBIO Key Metrics

Key financial metrics for BBIO
Metric	Value
Price	$67.69
Market Cap	$12.79B
P/E Ratio	-18.26
EPS	$-3.73
Dividend Yield	0.00%
52-Week High	$84.94
52-Week Low	$21.72
Volume	2.32M
Avg Volume	0
Revenue (TTM)	$579.96M
Net Income	$-729.88M
Gross Margin	95.13%

Recent BBIO Insider Trades

Scott Randal W. sold 6.20K (~$413.46K) on May 15, 2026.
Scott Randal W. sold 2.09K (~$141.00K) on May 15, 2026.
Scott Randal W. sold 1.51K (~$103.16K) on May 15, 2026.
Scott Randal W. sold 200 (~$13.82K) on May 15, 2026.
Kumar Neil sold 13.97K (~$931.31K) on May 8, 2026.

Latest BBIO News

BridgeBio Pharma Acoramidis Reduces All-Cause Death 44.7% and Cardiovascular Death 49.3% at 54 Months — May 12, 2026
BridgeBio Files Encaleret NDA After 76% Phase 3 Success, Targets Early 2027 Launch — May 12, 2026
BridgeBio’s Acoramidis Cuts sTTR Variability to 9.5% and Reduces Hospitalizations 34% — May 11, 2026
BridgeBio Pharma Posts $195M Q1 Revenue, Bernstein Raises Target to $114 — May 8, 2026
BridgeBio Q1 Revenues $194.5M, Initiates $500M Buyback and BBP-418 NDA — May 7, 2026

BBIO Analyst Consensus

17 analysts cover BBIO: 0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.00.

Common questions about BBIO

Who is trading BBIO stock inside the company?: Recent BBIO insider activity includes Scott Randal W. sold 6.20K, Scott Randal W. sold 2.09K, Scott Randal W. sold 1.51K, Scott Randal W. sold 200, and Kumar Neil sold 13.97K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BBIO?: Yes. Rallies tracks BBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.